KPV: the small end of alpha-MSH

KPV is about as simple as a bioactive peptide gets: three amino acids, lysine-proline-valine, and nothing else. Its interest comes from where it sits inside a bigger molecule. KPV is the tail end of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone with a long-studied link to pigmentation and inflammation signalling. Researchers noticed that this small C-terminal piece kept some of the anti-inflammatory character of the parent hormone while being far easier to make and study, which is why it draws attention in gut and immune-cell research.

For laboratory research use only. Not for human or veterinary use.

What the molecule actually is

KPV is the linear tripeptide L-lysyl-L-prolyl-L-valine, corresponding to residues 11 to 13 of alpha-MSH. Three standard L-amino acids, free ends, no metal and no modification: it is one of the smallest peptides in serious research use. The free-base molecular weight is about 342.4 g/mol, which puts it closer to a small molecule than to the larger peptides it often gets grouped with. That size is not a footnote; it shapes almost everything about how the molecule is studied.

A tripeptide is short enough to be recognised by peptide transporters, and much of the KPV literature turns on exactly that. The molecule is stable, water-soluble and straightforward to synthesise, so confirming identity is mostly a matter of routine mass spectrometry against the certificate of analysis. There is little room for ambiguity in a three-residue sequence, which is an advantage for reproducibility and a liability if a supplier cuts corners.

Verified molecule

• Sequence (1-letter): KPV
• Molecular formula: C16H30N4O4
• Molecular weight: 342.43 g/mol
• CAS number: 67727-97-3
• Class: linear tripeptide, alpha-MSH C-terminal fragment (residues 11 to 13)

What the literature examines

The central finding in the KPV literature is transport. A 2008 study by Dalmasso and colleagues in Gastroenterology reported that the peptide is taken into intestinal epithelial and immune cells through PepT1, a transporter that normally moves di- and tripeptides across the gut lining. Once inside, the peptide was associated with reduced inflammatory signalling, with the work pointing at the NF-kB pathway that drives many inflammatory gene programs. That gave the fragment a concrete mechanism rather than a vague reputation.

That combination, uptake through a known transporter plus interaction with a well-mapped signalling pathway, is what makes KPV a tidy model system. It also connects the tripeptide back to alpha-MSH, since the parent hormone is itself studied for anti-inflammatory signalling. The research so far concentrates on intestinal and immune-cell models rather than whole-organism outcomes, so the mechanism is clearer than the broader picture of what the peptide does in a living system.

It helps to place KPV against its parent. Alpha-MSH is a melanocortin peptide best known for pigment signalling, but it also carries anti-inflammatory activity through melanocortin receptors. KPV lacks the receptor-binding core that drives pigmentation, so it is studied as a fragment that appears to keep some of the anti-inflammatory character without the full melanocortin profile. That separation is much of the appeal for researchers who want to probe the inflammatory side of the hormone without the pigment-related activity coming along with it.

Why the tripeptide, not the hormone

Because KPV is so small, it doubles as a convenient probe for transporter biology. PepT1 is a proton-coupled transporter that shuttles di- and tripeptides across epithelial membranes, and a stable tripeptide that rides it makes a clean tool for asking how such cargo enters intestinal and immune cells. That is a large part of why the molecule shows up in gut-inflammation models: it pairs a defined route of entry with a defined signalling target, a combination that is rarer than it sounds. A researcher can ask both how the peptide gets in and what it does once inside using the same simple molecule, which is exactly the kind of tractability that keeps a fragment in circulation long after the parent hormone has been thoroughly mapped.

Where it came from

KPV was recognised as the minimal active C-terminal fragment of alpha-MSH during work on which part of the hormone carried its anti-inflammatory character. Alpha-MSH is a thirteen-residue hormone, and stripping it down to the final three residues produced a molecule that retained useful activity in models while being cheap and stable. The PepT1 transport story, worked out later, gave the fragment a clear mechanistic reason to be studied on its own rather than only as a piece of the parent hormone.

Honest limitations

The evidence is early and narrow. Most KPV work is in cell culture and rodent models of intestinal inflammation, and the peer-reviewed record does not contain the controlled human trials that would be needed to support strong claims. The signalling picture, while cleaner than for many peptides, is still assembled from model systems rather than definitive human data, and single findings should not be over-read.

There is also a purity caveat that follows from the chemistry. Short peptides are cheap to make, which unfortunately makes the market attractive to low-quality suppliers, and a three-residue sequence leaves little margin for error in synthesis. A lot-specific certificate of analysis and independent mass spectrometry are the sensible checks, since the molecule is too small to tolerate much uncertainty about what is actually in the vial.

None of this diminishes why KPV is studied; it just clarifies the stage the science is at. The transporter and pathway findings are real and repeatable within their model systems, and a molecule this well defined makes a good research subject precisely because it is simple. The gap is the familiar one for this field: the distance between a clean result in cultured cells or a rodent gut and any claim about a larger system has not been closed, and careful writing about the peptide keeps those two things firmly apart.

Common questions

What is KPV?

It is a linear tripeptide (lysine-proline-valine) that matches the last three residues of alpha-melanocyte-stimulating hormone. In research it is studied for uptake through the PepT1 transporter and for interaction with inflammatory signalling in intestinal and immune cells.

How does KPV relate to alpha-MSH?

KPV is the C-terminal fragment of alpha-MSH, residues 11 to 13 of the full hormone. It keeps part of the parent molecule's anti-inflammatory signalling character in model systems while being far smaller and simpler to work with in the lab.

How is it stored?

Like most lyophilised peptides it is kept dry, cold and out of light, with reconstituted material held cold and used promptly. The exact window depends on buffer and salt form, so the lot certificate of analysis is the reference rather than a generic figure.

References

1. Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008.